[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367282-105":59,"doc-detail-367282-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","in-silico-analysis-unveiling-the-role-of-cancer-stem-cells-in-immunotherapy-resistance-of-immune-checkpoint-high-pancreatic-adenocarcinoma","In-silico analysis unveiling the role of cancer stem cells in immunotherapy resistance of immune checkpoint-high pancreatic adenocarcinoma","","In-silico analyses mine cancer datasets with R2, clinical trial information, and Kaplan–Meier evaluation via GEPIA to compare immune checkpoint (IC) behavior across low- and high-responder cancers. Pancreatic adenocarcinoma shows high IC expression yet low immunotherapy response, with TIMER2.0 indicating enriched pro-tumor immune subsets and cancer-associated fibroblasts, but reduced antitumor immunity. cBioportal supports lower tumor mutational burden and specific driver mutations. Cancer stem cell signatures correlate with resistance, linking to immunoevasion and defining a CSC-centered rationale for personalized assessment and targeting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/in-silico-analysis-unveiling-the-role-of-cancer-stem-cells-in-immunotherapy-resistance-of-immune-checkpoint-high-pancreatic-adenocarcinoma/367282/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/in-silico-analysis-unveiling-the-role-of-cancer-stem-cells-in-immunotherapy-resistance-of-immune-checkpoint-high-pancreatic-adenocarcinoma/367282.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do some cancers show low response despite high immune checkpoint expression?","Question",{"text":112,"@type":113},"The study finds that pancreatic adenocarcinoma can express high immune checkpoints yet still show low immunotherapy response, explained by tumor biology beyond IC levels, especially cancer stem cell involvement.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does TIMER2.0 show about the tumor microenvironment in pancreatic adenocarcinoma?",{"text":117,"@type":113},"Compared with high-responder lung adenocarcinoma, pancreatic adenocarcinoma has higher pro-tumor immune subsets and cancer-associated fibroblasts, along with lower antitumor immune subsets.",{"name":119,"@type":110,"acceptedAnswer":120},"How are cancer stem cells connected to immunotherapy resistance in this analysis?",{"text":121,"@type":113},"Cancer stem cells (CSCs) are positively correlated with driver mutations, pro-tumor immune subsets, and CAFs, with CSC gene expression higher in pancreatic adenocarcinoma than in lung adenocarcinoma. CSC signature analyses further associate CSC-related programs with resistance genes and pro-cancer immune cells, while inversely relating to cytotoxic T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367282,1790197054,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIn-silico analysis unveiling the role of cancer stem cells in immunotherapy resistance of immune checkpoint-high pancreatic adenocarcinoma  \nUdit Basak1, Sumon Mukherjee1, Sourio Chakraborty1, Gaurisankar Sa1, Shubhra Ghosh Dastidar2􀀍 & Tanya Das1􀀍  \nAlthough immune checkpoint (IC) inhibition is a major treatment modality in cancer-immunotherapy, multiple cancers show low response. Our in-silico exploration by mining cancer datasets using R2, available clinical trial data, and Kaplan–Meier analysis from GEPIA depicted that unlike low-responder (LR) cancers, high-responder (HR) cancers furnish higher IC expression, that upon lowering may provide better prognosis. Contrastingly, pancreatic adenocarcinoma (PAAD) demonstrated high IC expression but low immunotherapy-response. Infiltration scores from TIMER2.0 revealed higher  \npro-tumor immune subsets and cancer-associated fibroblasts (CAFs) while depicting lower antitumor immune subsets in PAAD as compared to HR lung adenocarcinoma (LUAD). Additionally, bioinformatic tool cBioportal showed lesser tumor mutational burden, mismatch repair deficiency and greater percent of driver mutations inTP53, KRAS andCDKN2A in PAAD, supporting its higher immunotherapy-resistance than LUAD. Our search for the ‘key’ immunotherapy response-deciding factor(s) revealed cancer stem cells (CSCs), the known contributors of therapy-resistance and immunoevasion, to be positively correlated with above-mentioned driver mutations, pro-tumor immune and CAF subsets; and that PAAD furnished higher expression of CSC genes than LUAD. UMAP/tSNE analyses revealed that high CSC signature is positively correlated with immunotherapy-resistance genes and pro-cancer immune cells, while negatively with cytotoxic-T cells in PAAD. Our in-silico study explains the low immunotherapy-response in high IC-expressing PAAD, wherein CSC plays a pivotal role. Further exploration portrayed correlation of CSCs with immunotherapy-resistance in other LR and HR cancers too, substantiating the need for personalized CSC evaluation and targeting for successful immunotherapy outcomes.  \nKeywords Adenocarcinoma, Cancer stem cells, Immune checkpoint, Immunotherapy, In-silico study, Pancreatic, Resistance  \nCancer-immunotherapy has revolutionized cancer treatment and has achieved remarkably effective and durable responses in a subset of patients with different cancer types. However, most patients receiving these therapies, even in combination, do not derive clinical benefit1. In fact, around 20–40% of patients respond to immunotherapy2, among which immune checkpoint inhibitor (ICI) therapy has gained global attraction, leading upto 3 fold increase in number of clinical trials from 2017 to 20203. Immune checkpoints (ICs) like, programmed cell death 1 (PD1), cytotoxic T lymphocyte antigen 4 (CTLA4), lymphocyte activating gene-3 (LAG3) and T cell immunoglobulin and ITIM domain (TIGIT), are expressed on T cells and upon interacting with their respective ligands, act as brakes to limit the cytotoxic activity of T cells and inhibit their expansion, thereby, leading to tumor growth4,5. Among these, PD1 is mainly expressed on tumor-infiltrating lymphocytes (TILs) along with other immune cells that binds to PD ligand 1 (PDL1)/PDL2 on cancer cells and immune cells. Such interaction of PD1 with its ligands cause immune-tolerance, exhausted T cells and, low inflammatory  \n1Bose Institute, Centenary Campus, P-1/12, CIT Scheme VII M, Kolkata 700054, India. 2Bose Institute, Unified Academic Campus, EN 80, Sector V, Bidhannagar, Kolkata 700091, India. 􀀍 email: [sgd@jcbose.ac.in](sgd@jcbose.ac.in); [tanya@jcbose.ac.in](tanya@jcbose.ac.in)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nsignals6,7. FDA-approved immunotherapies targeting PD1 pathway have demonstrated encouraging responses in lung cancer and melanoma among others8. Another crucial IC mole","cbCaiohqNegwuWe6","https://ap.wps.com/l/cbCaiohqNegwuWe6","pdf",3968136,"English","# Introduction\n# Methods and In-silico Analyses\n## IC Expression and Prognostic Associations\n## Immune Infiltration and TME Profiling\n## Genomic Features and Mutation Patterns\n# Results Linking CSCs to Resistance\n## CSC Signature and Immunotherapy-Resistance Genes\n## CSCs in Other LR and HR Cancers\n# Conclusion and Implications","[{\"question\":\"Why do some cancers show low response despite high immune checkpoint expression?\",\"answer\":\"The study finds that pancreatic adenocarcinoma can express high immune checkpoints yet still show low immunotherapy response, explained by tumor biology beyond IC levels, especially cancer stem cell involvement.\"},{\"question\":\"What does TIMER2.0 show about the tumor microenvironment in pancreatic adenocarcinoma?\",\"answer\":\"Compared with high-responder lung adenocarcinoma, pancreatic adenocarcinoma has higher pro-tumor immune subsets and cancer-associated fibroblasts, along with lower antitumor immune subsets.\"},{\"question\":\"How are cancer stem cells connected to immunotherapy resistance in this analysis?\",\"answer\":\"Cancer stem cells (CSCs) are positively correlated with driver mutations, pro-tumor immune subsets, and CAFs, with CSC gene expression higher in pancreatic adenocarcinoma than in lung adenocarcinoma. CSC signature analyses further associate CSC-related programs with resistance genes and pro-cancer immune cells, while inversely relating to cytotoxic T cells.\"}]","In-silico analysis unveiling the role of cancer stem cells in immunotherapy resistance of immune checkpoint-high pancreatic adenocarcinoma | PDF",1790170071,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2519c9a7250b0e67129a4245cfe4980c.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be6276b17e30ef21f1b755833c3e49d7.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/428ffc0fc7dca9d79a00065e51c5ac37.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e17cbe9f5e1b617e63f6eb2bd9b6a07a.webp",980,1287]